Mechanisms involved in the effects of endothelin-1 in pig prostatic small arteries

European Journal of Pharmacology

Volumn 640, Issue 1-3, 2010, Pages 190-196

  Sánchez, Ana ^a   Recio, Paz ^a   Orensanz, Luis M ^b   Bustamante, Salvador ^c   Navarro Dorado, Jorge ^a   Climent, Belén ^a   Benedito, Sara ^a   García Sacristán, Albino ^a   Prieto, Dolores ^a   Hernández, Medardo ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Ca2+ channel; Endothelin ETA and ETB receptor; Endothelin 1; Kv channel; Nitric oxide; Pig prostatic small artery; Prostanoid; Vasoconstriction; Vasorelaxation

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; 4 AMINOPYRIDINE; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; APAMIN; CALCIUM CHANNEL L TYPE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GLIBENCLAMIDE; GUANYLATE CYCLASE; IBERIOTOXIN; INDOMETACIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYLENDOTHELIN 1 [6-21][11,15 ALANINE]; NIFEDIPINE; NITRIC OXIDE SYNTHASE; PROSTANOID; SODIUM CHLORIDE; TETRYLAMMONIUM; VOLTAGE GATED POTASSIUM CHANNEL; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; PEPTIDE FRAGMENT; POTASSIUM CHANNEL BLOCKING AGENT; PROSTAGLANDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EXTRACELLULAR CALCIUM; FORCE; MUSCLE CONTRACTILITY; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROSTATE; SWINE; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; VASOCONSTRICTION; VASODILATATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERY; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECTS; EXTRACELLULAR SPACE; IN VITRO STUDY; MALE; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIES; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; ENDOTHELIN-1; ENDOTHELINS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; EXTRACELLULAR SPACE; GUANYLATE CYCLASE; MALE; NITRIC OXIDE SYNTHASE; PEPTIDE FRAGMENTS; POTASSIUM CHANNEL BLOCKERS; PROSTAGLANDINS; PROSTATE; RECEPTORS, ENDOTHELIN; SWINE; VASOCONSTRICTION; ENDOTHELIN RECEPTOR ANTAGONISTS; IN VITRO TECHNIQUES;

EID: 77953811500     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.059     Document Type: Article

References (53)

1. Andersson K.-E. LUTS treatment: future treatment options. Neurourol. Urodyn. 2007, 26:934-947.
2. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730-732.
3. Arunlakshana O., Schild H.O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother. 1959, 14:48-52.
4. Baber S.R., Deng W., Rodriguez J., Master R.G., Bivalacqua T.J., Hyman A.L., Kadowitz P.J. Vasoactive prostanoids are generated from arachidonic acid by COX-1 and COX-2 in the mouse. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H1476-H1487.
5. Bhalla A., Haque S., Taylor I., Winslet M., Loizidou M. Endothelin receptor antagonism and cancer. Eur. J. Clin. Invest. 2009, 39(Suppl 2):74-77.
6. Chi K.N., Bjartell A., Dearnaley D., Saad F., Schröder F.H., Sternberg C., Tombal B., Visakorpi T. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur. Urol. 2009, 56:594-605.
7. Fizazi K., Miller K. Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer. B.J.U. Int. 2009, 104:1423-1425.
8. Fujitani Y., Ueda H., Okada T., Urade Y., Karaki H. A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta. J. Pharmacol. Exp. Ther. 1993, 267:683-689.
9. Fukuroda T., Fujikawa T., Ozaki S., Ishikawa K., Yano M., Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem. Biophys. Res. Commun. 1994, 199:1461-1465.
10. Golomb E., Rosenzweig N., Eilam R., Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J. Androl. 2000, 21:58-64.
11. Goto K., Hama H., Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J. Pharmacol. 1996, 72:261-290.
12. Henry P.J., Rigby P.J., Self G.J., Preuss J.M., Goldie R.G. Relationship between endothelin-1 binding site densities and constrictor activities in human and animal airway smooth muscle. Br. J. Pharmacol. 1990, 100:786-792.
13. Hiraoka Y., Oshita M., Morikawa K., Nagata O., Hahn K.J., Hahn A., Okada K., Taniguchi T., Muramatsu I. Characterization of the endothelin receptor subtypes in human prostate. J. Cardiovasc. Pharmacol. 2000, 36:S252-S254.
14. Hirata Y., Emori T., Eguchi S., Kanno K., Imai T., Ohta K., Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J. Clin. Invest. 1993, 91:1367-1373.
15. 125I]BQ3020 selective for endothelin (ETD) receptors. Life Sci. 1992, 51:PL47-PL52.
16. Imajo C., Walden P.D., Shapiro E., Doherty A.M., Lepor H. Evaluation of the effect of endothelin-1 and characterization of the selective endothelin a receptor antagonist PD155080 in the prostate. J. Urol. 1997, 158:253-257.
17. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. USA 1989, 86:2863-2867.
18. Kiowski W., Linder L., Stoschitzky K., Pfisterer M., Burckhardt D., Burkart F., Bühler F.R. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenous administered endothelin-1 in clinically healthy smokers. Circulation 1994, 90:27-34.
19. Kobayashi S., Tang R., Wang B., Opgenorth T., Langenstroer P., Shapiro E., Lepor H. Binding and functional properties of endothelin receptor subtypes in the human prostate. Mol. Pharmacol. 1994, 45:306-311.
20. Kondo S., Morita T., Tashima Y. Benign prostatic hypertrophy affects the endothelin receptor density in the human urinary bladder and prostate. Urol. Int. 1995, 54:198-203.
21. Langenstroer P., Tang R., Divish B., Opgenorth T., Shapiro E., Lepor H. Endothelins in canine genitourinary tissues. J. Urol. 1997, 157:1044-1048.
22. Langenstroer P., Tang R., Shapiro E., Divish B., Opgenorth T., Lepor H. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J. Urol. 1993, 150:495-499.
23. Latifpour J., Fukumoto Y., Weiss R.M. Regional differences in the density and subtype specificity of endothelin receptors in rabbit urinary tract. Naunyn Schmiedebergs Arch. Pharmacol. 1995, 352:459-468.
24. Lerman A., Edwards B.S., Hallett J.W., Heublein D.M., Sandberg S.M., Burnett J.C. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J. Med. 1991, 325:997-1001.
25. Lippton H.L., Cohen G.A., McMurtry I.F., Hyman A.L. Pulmonary vasodilation to endothelin isopeptides in vivo is mediated by potassium channel activation. J. Appl. Physiol. 1991, 70:947-952.
26. Matsuda H., Beppu S., Ohmori F., Yamada M., Miyatake K. Involvement of cyclo-oxygenase-generated vasodilating eicosanoid(s) in addition to nitric oxide in endothelin-1-in.duced endothelium-dependent vasorelaxation in guinea pig aorta. Heart Vessels 1993, 8:121-127.
27. Molenaar P., O'Reilly G., Sharkey A., Kuc R.E., Harding D.P., Plumpton C., Gresham G.A., Davenport A.P. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circulation 1993, 72:526-538.
28. Moriyama N., Kurimoto S., Miyata N., Yamaura H., Yamazaki R., Sudoh K., Inagaki O., Takenaka T., Kawabe K. Decreased contractile effect of endothelin-1 on hyperplastic prostate. Gen. Pharmacol. 1996, 27:1061-1065.
29. Mumtaz F., Dashwood M., Thompson C., Khan M., Naylor A., Mikhailidis D., Morgan R. Autoradiographic localisation and contractile properties of prostatic endothelin receptors in patients with bladder outlet obstruction. Eur. Urol. 2001, 39:48-56.
30. Mumtaz F.H., Dashwood M.R., Thompson C.S., Sullivan M.E., Mikhailidis D.P., Morgan R.J. Increased expression of endothelin B receptors in the diabetic rabbit urinary bladder: functional relevance. B.J.U. Int. 1999, 83:113-122.
31. Muramatsu M., Oka M., Morio Y., Soma S., Takahashi H., Fukuchi Y. Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs. Am. J. Physiol. 1999, 276:L358-L364.
32. Nakashima M., Vanhoutte P.M. Endothelin-1 and -3 cause endothelium-dependent hyperpolarization in the rat mesenteric artery. Am. J. Physiol. 1993, 265:H2137-H2141.
33. Navarro-Dorado J., Orensanz L.M., Recio P., Bustamante S., Benedito S., Martínez A.C., García-Sacristán A., Prieto D., Hernández M. Mechanisms involved in testosterone-induced vasodilatation in pig prostatic small arteries. Life Sci. 2008, 83:569-573.
34. Nelson J.B., Chan-Tack K., Hedican S.P., Magnuson S.R., Opgenorth T.J., Bova G.S., Simons J.W. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996, 56:663-668.
35. Ogawa Y., Nakao K., Arai H., Nakagawa O., Hosoda K., Suga S., Nakanishi S., Imura H. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem. Biophys. Res. Commun. 1991, 178:248-255.
36. Ozaki S., Ohwaki K., Ihara M., Fukuroda T., Ishikawa K., Yano M. ETB mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells. Biochem. Biophys. Res. Commun. 1995, 209:483-489.
37. Prayer-Galetti T., Rossi G.P., Belloni A.S., Albertin G., Battanello W., Piovan V., Gardiman M., Pagano F. Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate. J. Urol. 1997, 157:2334-2339.
38. Rajeshkumar N.V., Matwyshyn G., Gulati A. IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats. Prostate 2007, 67:701-713.
39. Recio P., Orensanz L.M., Martínez M.P., Navarro-Dorado J., Bustamante S., García-Sacristán A., Prieto D., Hernández M. Noradrenergic vasoconstriction of pig prostatic small arteries. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 376:397-406.
40. Riezebos J., Watts I.S., Vallance P.J. Endothelin receptors mediating functional responses in human small arteries and veins. Br. J. Pharmacol. 1994, 111:609-615.
41. Saita Y., Yazawa H., Koizumi T., Morita T., Tamura T., Takenaka T., Honda K. Mitogenic activity of endothelin on human cultured prostatic smooth muscle cells. Eur. J. Pharmacol. 1998, 349:123-128.
42. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348:732-735.
43. Salomonsson M., Sorensen C.M., Arendshorst W.J., Steendahl J., Holstein-Rathlou N.H. Calcium handling in afferent arterioles. Acta Physiol. Scand. 2004, 181:421-429.
44. Schoeffter P., Randriantsoa A., Jost B., Bruttel K. Comparative effects of the two endothelin ETA receptor antagonists, BQ-123 and FR139317, on endothelin-1-induced contraction in guinea-pig iliac artery. Eur. J. Pharmacol. 1993, 241:165-169.
45. Simonson M.S., Dunn M.J. Cellular signaling by peptides of the endothelin gene family. FASEB J. 1990, 4:2989-3000.
46. Tirapelli C.R., Casolari D.A., Yogi A., Montezano A.C., Tostes R.C., Legros E., D'Orléans-Juste P., de Oliveira A.M. Functional characterization and expression of endothelin receptors in rat carotid artery: involvement of nitric oxide, a vasodilator prostanoid and the opening of K+channels in ETB-induced relaxation. Br. J. Pharmacol. 2005, 146:903-912.
47. A receptor antagonist, on the lower urinary tract. Eur. J. Pharmacol. 2008, 580:394-400.
48. Wada K., Tabuchi H., Ohba R., Satoh M., Tachibana Y., Akiyama N., Hiraoka O., Asakura A., Miyamoto C., Furuichi Y. Purification of an endothelin receptor from human placenta. Biochem. Biophys. Res. Commun. 1990, 167:251-257.
49. Wada Y., Takahashi W., Latifpour J., Weiss R.M., Matsumoto K., Matsui K., Yamada G., Imamura T. Prostate expression of endothelins and their receptors in rat growth. Reprod. Fertil. Dev. 2008, 20:750-759.
50. Wei C.M., Lerman A., Rodeheffer R.J., McGregor C.G., Brandt R.R., Wright S., Heublein D.M., Kao P.C., Edwards W.D., Burnett J.C. Endothelin in human congestive heart failure. Circulation 1994, 89:1580-1586.
51. Wu-Wong J.R., Chiou W.J., Dickinson R., Opgenorth T.J. Endothelin attenuates apoptosis in human smooth muscle cells. Biochem. J. 1997, 328:733-737.
52. Yanagisawa M., Inoue A., Ishikawa T., Kasuya Y., Kimura S., Kumagaye S., Nakajima K., Watanabe T.X., Sakakibara S., Goto K. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide Proc. Natl. Acad. Sci. USA 1988, 85:6964-6967.
53. Zellers T.M., McCormick J., Wu Y. Interaction among ET-1, endothelium-derived nitric oxide, and prostacyclin in pulmonary arteries and veins. Am. J. Physiol. 1994, 267:H139-H147.